Previous 10 | Next 10 |
Investment Thesis Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. ( AXSM ) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be availab...
SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, announced today that th...
Sintx Technologies (NASDAQ: SINT ) +53% . More news on: Sintx Technologies, Inc., Valeritas Holdings, Inc., MDJM Ltd., Stocks on the move, Read more ...
VistaGen Therapeutics ( OTC:VTGN ) initiated with Outperform rating and $7 (+999% upside) price target at William Blair. Shares up 8% premarket. More news on: VistaGen Therapeutics, Inc., Catalent, Inc., Cerus Corporation, Healthcare stocks news, Stocks on the move, , Read ...
VistaGen Therapeutics ( OTC:VTGN ): Q1 GAAP EPS of -$0.15 misses by $0.04 . More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial resu...
Previously completed Phase 2a clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration Phase 2b clinical trial for treatment of Major Depressive Disorder (MDD) planned f...
VistaGen Therapeutics ( OTC:VTGN ): FY GAAP EPS of -$0.90 beats by $0.01 . More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 25, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its...
Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects SOUTH SAN FRANCISCO, CA / ACCESSWIRE...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...